QT prolongation: A case of arsenical pericardial and pleural effusion

Cardiovascular Toxicology

Volumn 8, Issue 1, 2008, Pages 41-44

  Vizzardi, Enrico ^a   Zanini, Gregoriana ^a   Antonioli, Elena ^a   D'Aloia, Antonio ^a   Raddino, Riccardo ^a   Cas, Livio Dei ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Arsenic trioxide; Cardiac tamponade; QT prolongation

Indexed keywords

AMIODARONE; ARSENIC TRIOXIDE; CORTICOSTEROID; STEROID;

AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAPHY; HEART ATRIUM FLUTTER; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; MALE; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; SYSTOLIC HEART MURMUR; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

AGED; ANTINEOPLASTIC AGENTS; ARSENICALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LONG QT SYNDROME; MALE; OXIDES; PERICARDIAL EFFUSION; PLEURAL EFFUSION; RECOVERY OF FUNCTION; WITHHOLDING TREATMENT;

EID: 49349098174     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12012-007-9009-4     Document Type: Article

References (11)

1. J. T. Barbey J. C. Pezzullo S. L. Soignet 2003 Effect of arsenic trioxide on QT interval in patients with advanced malignancies Journal of Clinical Oncology 21 3609 3615
2. Z. Shen G. Chen J. Ni 1997 Use of arsenic trioxide in the treatment of APL, clinical efficacy and pharmacokinetics in relapsed patients Blood 89 3354 3360
3. C. Niu H. Yan T. Yu 1999 Studies on treatment of acute promyelocytic leukaemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients Blood 94 3315 3324
4. S. L. Soignet S. R. Frankel D. Douer 2001 United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia Journal of Clinical Oncology 19 3852 3860
5. P. Westervelt R. A. Brown D. R. Adkins H. Khoury 2001 Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide Blood 98 266 271
6. M. S. Tallman J. W. Andersen C. A. Schiffer 1997 All trans retinoid acid in acute promyelocytic leukemia The New England Journal of Medicine 337 1021 1028
7. A. Chanan-Khan S. Srinivasan M. S. Czuczman 2004 Prevention and management of cardiotoxicity from antineoplastic therapy Journal of Supportive Oncology 2 3 251 256
8. R. L. Jones M. S. Ewer 2006 Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs Expert Review of Anticancer Therapy 6 9 1249 1269
9. B. Drolet C. Simard D. M. Roden 2004 Unusul effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents Circulation 109 26 29
10. A. Ghavamzade K. Alimoghaddam S. H. Ghaffari 2006 Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy Annals of Oncology 17 131 134
11. Klaassen, C. D. (2001). Heavy metals and heavy-metal antagonists. In J. G. Hardman, L. E. Limbird, & G. A. Goodman (Eds.), Goodman & Gilman's the pharmacological basis of therapeutics (pp. 1851-1875). New York: McGraw-Hill.